Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: Impact of the V264M substitution on plasma levels of TFPI

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 4, 1999, Pages 862-869

  Moatti, Didier ^a   Seknadji, Patrick ^b   Galand, Colette ^a   Poirier, Odette ^a   Fumeron, Frédéric ^c   Desprez, Sophie ^a   Garbarz, Michel ^a   Dhermy, Didier ^a   Arveiler, Dominique ^d   Evans, Alun ^e   Luc, Gerald ^d   Ruidavets, Jean Bernard ^d   Ollivier, Véronique ^a   Hakim, Jacques ^a   Aumont, Marie Claude ^b   De Prost, Dominique ^a,c  

^a INSERM   (France)

^b Service de Cardiologie   (France)

^c BICHAT HOSPITAL   (France)

^d MONICA Project   (France)

^e MONICA Project   (United Kingdom)

Author keywords

Case control studies; Genetics; Myocardial infarction; Tissue factor pathway inhibitor

Indexed keywords

ENOXAPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0032892214     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.4.862     Document Type: Article

References (31)

1. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
2. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71:1-8.
3. Marmur JD, Thiruvikraman SV, Fyfe BS, Guhu A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation. 1996;94:1226-1232.
4. Jude B, Agraou B, Mcfadden EP, Susen S, Bauters C, Lepelley P, Vanhaesbroucke C, Devos P, Cosson A, Asseman P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation. 1994;90:1662-1668.
5. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost. 1997;78:471-477.
6. Broze GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med. 1995;46:103-112.
7. van der Logt CPE, Reitsma PH, Bertina RM. Intron-exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor: the factor-Xa dependent inhibitor of the extrinsic pathway of coagulation. Biochemistry. 1991;30:1571-1577.
8. Girard TJ, Eddy R, Wesselschmidt RL, Macphail LA, Likert KM, Byers MG, Shows TB, Broze GJ Jr. Structure of the human lipoprotein-associated coagulation inhibitor gene: intron/exon gene organization and localization of the gene to chromosome 2. J Biol Chem. 1991;266: 5036-5041.
9. Tyson DR, Kuppuswamy MN, Broze GJ, Bajaj SP. Revised DNA sequence of exon 1 and 5′ flanking region of the human tissue factor pathway inhibitor gene. Thromb Res. 1993;70:269-273.
10. Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Schwartzman reaction. Blood. 1991;78:1496-1502.
11. Braunwald E. Unstable angina: a classification. Circulation. 1989;80: 410-414.
12. Cambien F, Poirier O, Lecerf L, Evans A, Cambou J, Arveiler D, Luc G, Bard J, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-eonverting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359: 641-644.
13. Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, McMaster D, Schaffer P, Douste-Blazy P, Luc G, Richard JL, Ducimetière P, Fruchart JC, Cambien F. A case-control study of lipoprotein particles in two populations at contrasting risk of coronary heart disease: the ECTIM study. Arterioscler Thromb. 1992;12:701-707.
14. WHO MONICA project principal investigators. The World Health Organization MONICA Project (MONitoring trends and determinants in CArdiovaseular disease): a major international collaboration, J Clin Epidemiol. 1988;41:105-114.
15. Wun TC, Kretemer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem. 1988:263:6001-6004.
16. Bell G, Karam J, Rutter W. Polymorphic DNA region adjacent to the 5′ end of the human insulin gene. Proc Natl Acad Sci U S A. 1981;78:5759-5763.
17. Lerman LS, Silverstein K. Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. Methods Enzymol. 1987;155:482-501.
18. Costes B, Girodon E, Ghanem N, Chassignol M, Thuong NT, Dupret D, Goossens M. Psoralen-modified oligonucleotide primers improve detection of mutations by denaturing gradient gel electrophoresis and provide an alternative to GC-clamping. Hum Mol Genet. 1993;2:393-397.
19. A2) of the glycoprotein IIIa (GPTIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemost. 1997;77:1179-1181.
20. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard U. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagulation Fibrinol. 1991;2:425-433.
21. Belaaouaj A, Kuppuswamy MN, Birktoft JJ, Bajaj SP. Revised cDNA sequence of rabbit tissue factor pathway inhibitor. Thromb Res. 1998;69: 547-553.
22. Girard TJ, Gailani D, Broze GJ. Complementary DNA sequencing of canine tissue factor pathway inhibitor reveals a unique nanomeric repetitive sequence between the second and third Kunitz domains. Biochem J. 1994;303:923-928.
23. Kamei S, Kamikubo Y, Fujimoto H, Ishihara M, Yonemura H, Miyamoto S, Funatsu A, Enjyoji K, Amubiya T, et al. Amino acid sequence and inhibitor activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI. J Biochem. 1994;115:708-714.
24. Kokawa T, Enjyoji K, Kumeda K, Kamikubo Y, Haradashiba M, Koh H, Tsushima M, Yamamoto A, Kato H. Measurement of the free form of TFPI antigen in hyperlipidemia: relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol. 1996;16: 802-808.
25. Bara L, Bloch ML, Zitoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier J. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res. 1993;69:443-452.
26. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (second part). N Engl J Med. 1992;326:310-318.
27. Wesselschmidt R, Liken K, Girard T, Wun TC, Broze GJ. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor-Xa. Blood. 1992;79:2004-2010.
28. Novotny WF, Palmier M, Wun TC, Broze GJ, Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. . 1991;78:394-400.
29. Ohkura N, Enjyoji K, Kamikubo Y, Kato H. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood. 1997;90:1883-1892.
30. Warshawsky I, Bu GJ, Mast A, Saffitz JE, Broze GJ, Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest. 1995;95: 1773-1781.
31. Sandset PM, Bendz B. Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost. 1997;78:467-470.